Neurocrine Biosciences Inc., of San Diego, completed its private offering of 517.5 million aggregate principal amount of its 2.25 percent convertible senior notes due 2024, which includes $67.5 million aggregate principal amount of notes that were sold pursuant to the exercise of the initial purchasers' option to purchase additional notes.